169 NSCLC patients from ten institutions were evaluated for PD-L1 expression by IHC, TMB, and cell proliferation by RNA-seq of 10 immune and proliferation related genes including BUB1, CCNB2, CDK1, CDKN3, FOXM1, KIAA0101, MAD2L1, MELK, MKI67, and TOP2A, of which 46 represented historical controls and 113 had prior treatment with one more immune checkpoint inhibitors (ICIs) and for which response (RECIST v1.1) and survival were available. Here, MKI67 is linked to non-small cell lung carcinoma.